TIXiMED

Executive Summary

TIXiMED is a clinical-stage biotechnology company pioneering oral small molecule inhibitors of thioredoxin-interacting protein (TXNIP) for metabolic diseases. Its lead candidate, TIX100, is a first-in-class TXNIP inhibitor initially targeting Type 1 and Type 2 Diabetes, as well as metabolic dysfunction–associated steatotic liver disease (MASLD). TXNIP is a key regulator of glucose and lipid metabolism, and its inhibition represents a novel approach to improve insulin sensitivity, reduce oxidative stress, and attenuate hepatic steatosis. Founded in 2017 and based in San Diego, the company aims to address significant unmet needs in diabetes and MASLD, where existing therapies offer limited efficacy or tolerability. TIX100's oral bioavailability and differentiated mechanism may position it as a potential cornerstone therapy across the metabolic disease spectrum, with preclinical data demonstrating robust glycemic control and liver fat reduction. The company is currently advancing TIX100 through early clinical development, with a clear focus on generating proof-of-concept data in patients.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for TIX100 in Type 2 Diabetes60% success
• Q1 2027Completion of preclinical IND-enabling studies for TIX100 in MASLD70% success
• Q3 2026Strategic partnership or licensing deal for TIX100 ex-US rights40% success